iPath Pure Beta Sugar ETN
SGAR
SGAR was delisted on the 11th of April, 2018.
1 hedge funds and large institutions have $34K invested in iPath Pure Beta Sugar ETN in 2017 Q3 according to their latest regulatory filings, with funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 0 closing their positions.
17% less capital invested
Capital invested by funds: $41K → $34K (-$7K)
50% less funds holding
Funds holding: 2 → 1 (-1)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$207 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
UBS Group
Zurich,
Switzerland
| $34K | -$207 | -9 | -0.6% |
|
SGAR Hedge Fund Activity: Q3 2017 in Review
1 of the 4,012 institutional investors tracked by Wall St. Rank reported a position in iPath Pure Beta Sugar ETN (SGAR) for Q3 2017, worth a combined $34K — down 17% from $41K a quarter earlier.
Fund positioning in SGAR was balanced in Q3 2017: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 1 trimmed.
The largest seller was UBS Group, cutting an estimated $207.
- 1 institutional investor held iPath Pure Beta Sugar ETN (SGAR) as of Q3 2017, down from 2 in Q2 2017.
- Funds reported $34K of iPath Pure Beta Sugar ETN stock for Q3 2017, down 17% quarter-over-quarter.
- 0 funds opened new iPath Pure Beta Sugar ETN positions in Q3 2017 and 0 closed out.
- The largest iPath Pure Beta Sugar ETN seller in Q3 2017 was UBS Group, an estimated $207 sold.
Based on aggregated 13F filings for Q3 2017.